Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medico RemediesNSE:MEDICO -1.41%85 EV-to-EBITDA is 15.95 as of Aug. 20, 2026, which is 42% below its 10-year median of 27.32. GuruFocus rates NSE:MEDICO with a GF Score™ of 85/100 and a GF Value™ of ₹77.46 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 736 Drug Manufacturers companies, Medico Remedies ranks worse than 58.7% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medico Remedies's enterprise value is ₹3,662 Mil.
Medico Remedies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹230 Mil. Therefore, Medico Remedies's EV-to-EBITDA for today is 15.95.
The historical rank and industry rank for Medico Remedies's EV-to-EBITDA or its related term are showing as below:
NSE:MEDICO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.77 Med: 27.32 Max: 116
Current: 15.95
During the past 13 years, the highest EV-to-EBITDA of Medico Remedies was 116.00. The lowest was 13.77. And the median was 27.32.
NSE:MEDICO's EV-to-EBITDA is ranked worse than 58.7% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs NSE:MEDICO: 15.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medico Remedies's PE Ratio (TTM) for today is calculated as:
Medico Remedies's share price for today is ₹42.07.
Medico Remedies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medico Remedies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medico Remedies's EV-to-EBITDA falls into.
Medico Remedies's current Enterprise Value is ₹3,662 Mil.
Medico Remedies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹230 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medico Remedies (NSE:MEDICO) has a EV-to-EBITDA of 15.95 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medico Remedies. This is 42% below median its historical median of 27.32. Over the past decade, Medico Remedies' EV-to-EBITDA has ranged from 13.77 to 116.00. According to the industry distribution chart, Medico Remedies ranks #432 out of 736 companies in the Drug Manufacturers industry, placing it in the top 58.7%.
Is Medico Remedies' EV-to-EBITDA too high?
Medico Remedies' current EV-to-EBITDA of 15.95 is 42% below median its 10-year median of 27.32. Over the past 10 years, this metric has ranged from a low of 13.77 to a high of 116.00. The Drug Manufacturers industry median EV-to-EBITDA is 13.31. Medico Remedies' value of 15.95 is 19.9% above this industry median. Based on the distribution chart, Medico Remedies ranks #432 out of 736 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medico Remedies has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medico Remedies ranks #432 out of 736 companies for EV-to-EBITDA. This places Medico Remedies in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. Medico Remedies' value of 15.95 is 19.9% above this benchmark. Historically, Medico Remedies' own EV-to-EBITDA has ranged from 13.77 to 116.00 over the past decade. While the company's 10-year median is 27.32 vs. the industry median of 13.31, Medico Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medico Remedies's current EV-to-EBITDA of 15.95 is 19.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medico Remedies. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medico Remedies's current EV-to-EBITDA is 15.95, which is 42% below median its own 10-year median of 27.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹77.46, compared to a current price of ₹42.07 — trading 45.7% below its estimated fair value. The current EV-to-EBITDA is 15.95, which is 42% below median its 10-year median of 27.32 and 19.9% above the Drug Manufacturers industry median of 13.31. Medico Remedies' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current EV-to-EBITDA is 15.95 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹42.07 is trading 45.7% below its estimated GF Value™ of ₹77.46.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for NSE:MEDICO:
EV-to-EBITDA: 15.95 (42% below median its 10-year median of 27.32)
GF Value™: ₹77.46 vs. price of ₹42.07 (45.7% below fair value)
Industry Position: 19.9% above the Drug Manufacturers median (#432 of 736)
No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
85GF Score
Get the complete analysis for NSE:MEDICO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDICO has been successfully added to your 
